使用聚多卡醇静脉内微泡沫改善具有挑战性临床表现患者的血流动力学和症状:病例系列
该回顾性病例系列纳入10例C3-C6慢性静脉功能不全且合并复杂病变限制热消融的患者,评估美国食品药品监督管理局批准的1%聚多卡醇静脉内微泡沫(PEM;Varithena®)对静脉症状的影响;治疗后4天和6周疼痛评分与静脉临床严重程度评分(VCSS)降低并维持至1年,结论认为PEM在热消融非最佳治疗的患者中改善了VCSS、症状和创面愈合。
要点
- 10例C3-C6慢性静脉功能不全合并复杂病变限制热消融的患者接受1%聚多卡醇静脉内微泡沫治疗。
- 治疗后4天和6周疼痛评分与VCSS降低,并维持至治疗后1年。
- PEM在热消融非最佳治疗的患者中改善了VCSS、症状和创面愈合。
核心结论
- 在热消融非最佳治疗的C3-C6患者中,使用聚多卡醇静脉内微泡沫成功改善了VCSS、慢性静脉功能不全症状和创面愈合。
研究设计与样本
- 回顾性综述,纳入10例(n=10)C3-C6慢性静脉功能不全患者,合并限制热消融的复杂疾病或病理。
- 病理包括瘀伤或出血风险、严重脂性硬皮病、化脓性汗腺炎、既往浅表血栓形成所致静脉慢性纤维化、神经损伤风险及既往热消融失败。
- 治疗前所有患者接受双功能超声静脉功能不全检查,记录术前疼痛、症状和静脉临床严重程度评分(VCSS)。
- 治疗后4天、6周、6个月和1年进行临床评估和双功能超声检查。
主要发现
- 双功能超声显示大隐静脉、大隐静脉前副支和/或小隐静脉存在反流。
- 治疗后4天和6周疼痛评分和VCSS降低,且这些较低评分维持至治疗后1年。
临床怎么用
- 原文结论认为PEM在热消融非最佳治疗的C3-C6患者中改善了VCSS、症状和创面愈合,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic venous insufficiency (CVI) is a widely prevalent condition. Saphenous venous reflux is the most common underlying pathology that leads to CVI. Endovenous thermal ablations (ETA) are the current gold standard. However, some patients present with some unique challenges making ETA less ideal. Nonthermal nontumescent therapies could be considered as alternative therapy in these patients. METHODS: We performed a retrospective review of treatment effects with United States Food and Drug Administration-approved polidocanol endovenous microfoam (PEM; Varithena® 1%) on venous symptomology in 10 (n = 10) C3-C6 patients with CVI and concomitant complex disease/pathology that limited the use of ETA. The pathology included risk of bruising or bleeding, severe lipodermatosclerosis, hidradenitis suppurativa, chronic fibrosis of the vein from prior superficial thrombosis, risk for nerve injury, and failed prior ETA. Before treatment, all patients underwent a venous incompetence study by duplex ultrasound (DUS). Preprocedure pain, symptoms, and Venous Clinical Severity Scores (VCSSs) were recorded. Clinical assessments and DUS were performed 4 days, 6 weeks, 6 months, and 1 year after treatment. RESULTS: DUS demonstrated reflux in the great saphenous vein (GSV), anterior accessory GSV, and/or the small saphenous vein. Pain scores and VCSS were reduced 4 days and 6 weeks after treatment. These lower scores were maintained for up to 1 year after treatment. CONCLUSIONS: PEM use in C3-C6 patients resulted in successful improvement in VCSS, CVI symptoms, and wound healing among patients in whom ETA was not considered to be the optimal therapy.
引用
- Davis PE, Phillips J, Kolluri R, et al. Use of Polidocanol Endovenous Microfoam to Improve Hemodynamics and Symptomology in Patients with Challenging Clinical Presentations: A Case Series. Ann Vasc Surg. 2018. PMID: 29772321. doi:10.1016/j.avsg.2018.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。